Literature DB >> 35522286

Effect of Mailing an At-home Disposal Kit on Unused Opioid Disposal After Surgery: A Randomized Clinical Trial.

Anish K Agarwal1,2,3, Daniel Lee2,4, Zarina Ali2,5, Yaxin Wu1, Mary Cognilio6, Tanya Uritsky6, M Kit Delgado1,2,3,7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35522286      PMCID: PMC9077482          DOI: 10.1001/jamanetworkopen.2022.10724

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


× No keyword cloud information.

Introduction

Many prescription opioids after surgery are left unused and are at risk of being misused.[1,2] Encouraging proper disposal is important, yet motivating this behavior remains challenging because patients must understand the risks of opioid use and the benefits of disposal and identify methods of safe disposal.[3] We sought to test the effect of a mailed at-home disposal kit on disposal rates of unused opioids after surgery.

Methods

This 2-arm, randomized clinical trial compared usual care vs a mailed at-home disposal kit that was embedded in an existing postoperative text messaging program designed to capture patient-reported outcomes data and self-reported disposal.[4] The trial protocol is available in Supplement 1. The study was approved by the University of Pennsylvania Institutional Review Board with a waiver of informed consent. The trial took place from April 19 to June 1, 2021, and followed the CONSORT reporting guideline. All patients 18 years or older undergoing an orthopedic or urologic procedure and prescribed an opioid replied through a text messaging platform using an established protocol.[5] Patients without access to a short messaging service–capable device or who did not speak English were excluded. Participants were electronically block randomized in groups of 2 or 4 to usual care or a mailed at-home disposal kit immediately after consent (eMethods in Supplement 2). Usual care consisted of a text message hyperlink to nearby disposal locations. Intervention participants were mailed an at-home disposal kit timed to arrive on postoperative day 4 to 7 based on prior data and designed to provide patients with a disposal method when they were most likely to be finished taking opioids.[5] The disposal kit (DisposeRx Inc.) sequesters tablets in a polymer gel. Patients self-reported disposal via text messaging. Baseline self-reported disposal rates were 25% to 30%. We estimated 75 patients per group, assuming a 2-sided α = .025, a β of 80%, and a 50% relative increase in self-reported disposal. The primary outcome of interest was self-reported disposal. All randomized participants were included in an intention-to-treat analysis, and statistical analyses were performed using Fisher exact and χ2 tests via R, version 3.60 (R Project for Statistical Computing).

Results

Of 657 patients invited to participate, 302 (46.0%) consented. Demographic information was obtained from the electronic health record to evaluate characteristics of respondents and nonrespondents. Participants had a median age of 56.5 (IQR, 40.0-65.8) years; 136 (45.0%) were women and 166 (55.0%) were men; 240 (79.5%) were White and 44 (14.6%) were Black; and 235 (77.8%) completed all questions. Consenting participants were younger than individuals who declined or did not respond (median age, 59.0 [IQR, 47.0-68.0] years), and more consenting participants than nonparticipants were White (215 of 355 [60.6%]). Participants were more likely than nonparticipants to be opioid naive (225 of 302 [74.5%] vs 225 of 355 [63.4%]) (Table 1). The odds of self-reported disposal were 2.01 (95% CI, 1.2-3.4) times higher in the intervention group. Among the 235 participants who completed all questions, 47 of 110 (42.7%) in the usual care group self-reported disposal, compared with 75 of 125 (60.0%) in the intervention group (Table 2). An estimated additional 480 unused opioid tablets were disposed of in the intervention group.
Table 1.

Participant Characteristics

CharacteristicParticipant groupNo response or declined (n = 355)P value
Intervention (n= 159)Control (n = 143)
Age, median (IQR), y55.0 (36.5-65.5)57.0 (41.0-65.5)59.0 (47.0-68.0).01
Sex
Women71 (44.7)65 (45.5)164 (46.2).76
Men88 (55.3)78 (54.5)189 (53.2)
Race
American Indian1 (0.6)0 0 .002
Asian4 (2.5)2 (1.4)12 (3.4)
Black26 (16.4)18 (12.6)108 (30.4)
East Indian00 2 (0.6)
White124 (78.0)116 (81.1)215 (60.6)
Otherb3 (1.9)4 (2.8)8 (2.3)
Patient declined0 1 (0.7)3 (0.8)
Unknown1 (0.6)2 (1.4)5 (1.4)
Hispanic ethnicity
Black1 (0.6)0 4 (1.1).09
White1 (0.6)0 10 (2.8)
Anxiety15 (9.4)10 (7.0)38 (10.7).50
Opioid naive117 (73.6)108 (75.5)225 (63.4).03
Opioid use disorder01 (0.7)5 (1.4).38
Alcohol use disorder2 (1.3)0 4 (1.1).49
Smoker4 (2.5)2 (1.4)9 (2.5).71
NSAID use52 (32.7)61 (42.7)126 (35.5).27

Abbreviation: NSAID, nonsteroidal anti-inflammatory drug.

Unless otherwise indicated, data are expressed as number (%) of participants.

Includes Native Hawaiian, other Pacific Islander, and more than 1 race.

Table 2.

Self-reported Opioid Disposal

CharacteristicParticipant groupa
Usual care (n = 110)Intervention (n = 125)
Self-reported disposal47 (42.7)75 (60.0)
Day
416 (14.5)17 (13.6)
718 (16.4)26 (20.8)
147 (6.4)27 (21.6)
216 (5.5)5 (4.0)
2800
Day of disposal, median (IQR)7 (4-14)7 (7-14)

Includes the 235 participants who completed all questions. Unless otherwise indicated, data are expressed as number (%) of participants.

Abbreviation: NSAID, nonsteroidal anti-inflammatory drug. Unless otherwise indicated, data are expressed as number (%) of participants. Includes Native Hawaiian, other Pacific Islander, and more than 1 race. Includes the 235 participants who completed all questions. Unless otherwise indicated, data are expressed as number (%) of participants.

Discussion

Opioid disposal remains important, but motivating disposal remains challenging. In this randomized clinical trial, a mailed at-home disposal kit increased self-reported opioid disposal rates after common surgical procedures. Efforts to encourage disposal are growing, yet research in scalable and patient-centered approaches is lacking. The demonstrated impact has high potential for a low cost solution. This study is limited in that it relied on self-reported disposal and reflects a single center’s experience; in addition, consenting patients were more likely to be younger and White, which limits generalizability. However, the findings build on literature suggesting that providing patients with at-home disposal options can improve self-reported disposal rates.[6] The process of mailing the disposal kit is simple, inexpensive (approximately $1.50 per mailed kit), and scalable.
  5 in total

1.  Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures.

Authors:  Maureen V Hill; Michelle L McMahon; Ryland S Stucke; Richard J Barth
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

2.  Effect of an Activated Charcoal Bag on Disposal of Unused Opioids After an Outpatient Surgical Procedure: A Randomized Clinical Trial.

Authors:  Chad M Brummett; Rena Steiger; Michael Englesbe; Caitlin Khalsa; Jennie J DeBlanc; Lindsay R Denton; Jennifer Waljee
Journal:  JAMA Surg       Date:  2019-06-01       Impact factor: 14.766

3.  Medication Sharing, Storage, and Disposal Practices for Opioid Medications Among US Adults.

Authors:  Alene Kennedy-Hendricks; Andrea Gielen; Eileen McDonald; Emma E McGinty; Wendy Shields; Colleen L Barry
Journal:  JAMA Intern Med       Date:  2016-07-01       Impact factor: 21.873

4.  Patient-Reported Opioid Consumption and Pain Intensity After Common Orthopedic and Urologic Surgical Procedures With Use of an Automated Text Messaging System.

Authors:  Anish K Agarwal; Daniel Lee; Zarina Ali; Brian Sennett; Ruiying Xiong; Jessica Hemmons; Evan Spencer; Dina Abdel-Rahman; Rachel Kleinman; Hannah Lacko; Annamarie Horan; Mary Dooley; Eric Hume; Samir Mehta; M Kit Delgado
Journal:  JAMA Netw Open       Date:  2021-03-01

Review 5.  Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review.

Authors:  Mark C Bicket; Jane J Long; Peter J Pronovost; G Caleb Alexander; Christopher L Wu
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.